“Every day is a new adventure!” This is often my response when someone asks how I’m doing. It also seems appropriate when looking forward to what 2022 may hold for me. I faithfully use my calendar to keep track of many tasks, both professional and personal. Before I was…
Lab-made versions of naturally occurring forms of nitro oleic acid effectively treated established pulmonary fibrosis (PF) in a mouse model, a study reports. These findings support the further development of these agents for reversing fibrosis, or tissue scarring, in the lungs and other organs, its scientists noted. The study,…
About half of the healthy older adults given PureTech’s anti-fibrotic therapy LYT-100 (deupirfenidone) were less likely to report gastrointestinal (GI) side effects compared with those given Esbriet (pirfenidone), according to a recent crossover study. Based on these findings, data to date from LYT-100’s clinical program and regulatory feedback, the…
MannKind Corporation has extended its collaboration with Thirona Bio to continue work toward an inhaled therapy for fibrotic diseases affecting the lungs, including idiopathic pulmonary fibrosis (IPF). Under a collaboration established last year, the companies are evaluating the therapeutic potential of FBM5712, an investigational medicine designed to…
If left untreated by anti-fibrotic medications, idiopathic pulmonary fibrosis (IPF) has a 50% mortality rate after three years, according to a recent observational study using real-world data. This is compared with a 26–31% mortality rate among IPF patients taking available anti-fibrotics, such as Esbriet (pirfenidone) and Ofev…
I thought I understood the role of a caregiver. It was based on what I learned and observed watching others. It turns out I did not fully appreciate the role until I had a caregiver. The role of the caregiver is not a single responsibility, but a collection of…
Treatment with either Ofev (nintedanib) or Esbriet (pirfenidone) — both antifibrotic therapies, but with different mechanisms of action — “offers protection” and can slow lung function decline in people with pulmonary fibrosis (PF), according to a new analysis. Moreover, the results showed that these medications can significantly reduce…
Pulmonary Fibrosis News brought you daily coverage throughout 2021 of the latest scientific findings, treatment developments, and clinical trials related to pulmonary fibrosis (PF). As a reminder of what mattered most to you during the past year, here are the top 10 most-read articles of 2021, with a brief…
I have tried countless times to describe idiopathic pulmonary fibrosis (IPF). In 2019, I tried to explain what it physically feels like, but I still can’t find words that adequately convey how hard living with IPF is, especially as it progresses. I never do the experience justice. Since most…
Idiopathic pulmonary fibrosis (IPF) patients with increased formation of type VI collagen — a major extracellular matrix (ECM) molecule involved in wound healing and scarring — are at higher risk of having progressive disease, a real-world study shows. Also, type VI collagen breakdown tended to increase in patients with progressive…
Get regular updates to your inbox.
